<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942019000100035</article-id>
<article-id pub-id-type="doi">10.30827/ars.v60i1.8219</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Elaboración de una guía de Seguimiento Farmacoterapéutico en el paciente con epilepsia]]></article-title>
<article-title xml:lang="en"><![CDATA[Development of a medication review with follow-up guide on patients with epilepsy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torralba Fernández]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amador Fernández]]></surname>
<given-names><![CDATA[Noelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Granada  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Granada Cátedra María José Faus Dáder de Atención Farmacéutica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>60</volume>
<numero>1</numero>
<fpage>35</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942019000100035&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942019000100035&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942019000100035&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Elaborar una guía práctica de seguimiento farmacoterapéutico (SFT) en el paciente con epilepsia tras el análisis de la información disponible, dirigida a todos los profesionales sanitarios involucrados en la atención del paciente, centrada en el farmacéutico comunitario.  Método: Se llevó a cabo una revisión bibliográfica con fecha límite del 15 de junio de 2017. La estrategia de búsqueda consistió en una revisión de fuentes prefiltradas de evidencia en epilepsia, guías de Atención Farmacéutica y Seguimiento Farmacoterapéutico, libros de farmacología humana y dispensación de medicamentos, bases de datos de evidencia científica y bases de datos del medicamento.  Resultados: Durante la realización del SFT en el paciente con epilepsia, se debe evaluar el tratamiento mediante la presencia de indicadores de necesidad (existencia del problema de salud que justifica su uso), efectividad (ausencia o disminución del número de crisis epilépticas) y seguridad (ausencia de efectos adversos, contraindicaciones e interacciones). Todo ello para diseñar una estrategia de intervención con el paciente y/o el resto de los profesionales sanitarios involucrados con el fin de mejorar la calidad de vida del paciente.  Conclusiones: Esta guía pretende ser un recurso útil para el farmacéutico comunitario en la realización del SFT en el paciente con epilepsia, puesto que contiene toda la información necesaria acerca de la enfermedad y los tratamientos empleados. Siempre considerando al paciente como una unidad, no fraccionado en función de sus problemas de salud.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Aim: Prepare a document to conduct medication review with follow-up of patients diagnosed with epilepsy. This document is been addressed to every health professional who take care of the patient, especially to community pharmacists.  Method: A literature review has been performed over the available resources until 15 June 2017. The search strategy considers sources of evidence in epilepsy, pharmaceutical care and medication review with follow-up guides, human pharmacology and dispensing books, drugs databases and scientific evidence databases. Results: In the application of the medication review with follow-up of patients with epilepsy, the treatment should be assessed through indicators of necessity (existence of a health problem that justifies the use of anticonvulsants), effectiveness (absence or decrease of the number of epileptic seizures) and safety (absence of adverse reactions, contraindications and interactions). This allows the appropriate co-design of an intervention strategy in collaboration with the patient and/or other health-care providers to improve the patients&#8217; quality of life.  Conclusions: This guide includes detailed information about the epilepsy and the treatments used by considering the patient as a unit and not divided according to their health problems. Therefore, this guide could be a useful tool tailored to those pharmacists involved in the medication review with follow-up of patients with epilepsy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[epilepsia]]></kwd>
<kwd lng="es"><![CDATA[antiepilépticos]]></kwd>
<kwd lng="es"><![CDATA[atención farmacéutica]]></kwd>
<kwd lng="es"><![CDATA[seguimiento farmacoterapéutico]]></kwd>
<kwd lng="en"><![CDATA[epilepsy]]></kwd>
<kwd lng="en"><![CDATA[anticonvulsants]]></kwd>
<kwd lng="en"><![CDATA[pharmaceutical services]]></kwd>
<kwd lng="en"><![CDATA[medication review with follow-up]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Sociedad Española de Neurología</collab>
<source><![CDATA[Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012.1. Guía oficial de práctica clínica en epilepsia]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Luzán 5]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ILAE classification of the epilepsies Position Paper of the ILAE Commission for Classification and Terminology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheffer]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Berkovic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Capovilla]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Conolly]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guilhoto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2017</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>512-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Instruction manual for the ILAE 2017 operational classification of seizure types]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[D'Souza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Haut]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Higurashi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2017</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>531-42</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Informe FEEN sobre la epilepsia en España]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Ramos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Masjuan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurologia]]></source>
<year>2011</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>548-55</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano-Castro]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mauri-Llerda]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Ramos]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Álvarez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Parejo-Carbonell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga-Subirana]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sci World]]></article-title>
<collab>et al »,» ®,® §,§ ­,­ ¹,¹ ²,² ³,³ ß,ß Þ,Þ þ,þ ×,× Ú,Ú ú,ú Û,Û û,û Ù,Ù ù,ù ¨,¨ Ü,Ü ü,ü Ý,Ý ý,ý ¥,¥ ÿ,ÿ ¶,¶ Adult prevalence of epilepsy in Spain: EPIBERIA.a Population-Based Study »,» ®,® §,§ ­,­ ¹,¹ ²,² ³,³ ß,ß Þ,Þ þ,þ ×,× Ú,Ú ú,ú Û,Û û,û Ù,Ù ù,ù ¨,¨ Ü,Ü ü,ü Ý,Ý ý,ý ¥,¥ ÿ,ÿ ¶,¶</collab>
<source><![CDATA[]]></source>
<year>2015</year>
<volume>2015</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios.AEMPS</collab>
<source><![CDATA[Utilización de medicamentos antiepilépticos en España durante el periodo 2008-2016]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[AEMPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabater]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Método Dáder: Guía de Seguimiento Farmacoterapéutico]]></source>
<year>2007</year>
<edition>3a ed.</edition>
<publisher-loc><![CDATA[Granada ]]></publisher-loc>
<publisher-name><![CDATA[Grupo de investigación en Atención Farmacéutica (GIAF)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<collab>Grupo de investigación en Atención Farmacéutica de la Universidad de Granada: conSIGUE</collab>
<source><![CDATA[Programa para la implantación y futura sostenibilidad del servicio de seguimiento farmacoterapéutico en la farmacia comunitaria española]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<collab>Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada: conSIGUE</collab>
<source><![CDATA[Medida del impacto clínico, económico y humanístico del servicio de seguimiento farmacoterapéutico en mayores polimedicados en la farmacia comunitaria española]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Variables psicosociales en el seguimiento farmacoterapéutico de personas con epilepsia en Colombia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Vacca]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Simbaqueba]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Vitae-Columbia]]></source>
<year>2012</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>270-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[People with epilepsy What do they know and understand, and how does this contribute to their perceived level of stigma?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2002</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>26-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myths, misconceptions, and misunderstandings about epilepsy in a Nigerian rural community Implications for community health interventions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osungbade]]></surname>
<given-names><![CDATA[KO]]></given-names>
</name>
<name>
<surname><![CDATA[Siyanbade]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2011</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Are what people know about their epilepsy and what they want from an epilepsy service related]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Minchin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stubbs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fenwick]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<source><![CDATA[Seizure]]></source>
<year>1997</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>436-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[What do people with epilepsy know about their condition Evaluation of a subspecialty clinic population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coker]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Bhargava]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<source><![CDATA[Seizure]]></source>
<year>2011</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An exploratory study of primary care pharmacist-led epilepsy consultations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fogg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Staufenberg]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Small]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bhattacharya]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm Pract]]></source>
<year>2012</year>
<volume>20</volume>
<page-range>294-302</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[La calidad de vida de los pacientes epilépticos determinada por la aplicación de la escala QOLIE-31]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[FN]]></given-names>
</name>
<name>
<surname><![CDATA[Arceo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurol Neurocir Psiquat]]></source>
<year>2007</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>50-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Non-compliance with anticonvulsant therapy as a cause of seizures]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanaway]]></surname>
<given-names><![CDATA[LLD]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<source><![CDATA[N Z Med J]]></source>
<year>1985</year>
<volume>98</volume>
<page-range>150-2</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Factors influencing compliance with antiepileptic drug regimen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jacoby]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Chadwick]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<source><![CDATA[Seizure]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>87-93</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poole]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients&amp;apos; perspectives on services for epilepsy; a survey of patients satisfaction, preferences and information provision in 2394 people with epilepsy]]></article-title>
<collab>McCarty M et al</collab>
<source><![CDATA[Seizure]]></source>
<year>2000</year>
<volume>9</volume>
<page-range>551-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A systematic overview A decade of research: the information counselling needs of people with epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Couldridge]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[March]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Seizure]]></source>
<year>2001</year>
<volume>10</volume>
<page-range>605-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of pharmacists in the management of patients with epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koshy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm Pract]]></source>
<year>2011</year>
<volume>20</volume>
<page-range>65-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of a pharmaceutical care programme on health-related quality of life among women with epilepsy a randomised controlled trial (IPHIWWE study)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Losada-Camacho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Pabon]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[García-Delgado]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Health Qual Life Out]]></source>
<year>2014</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>162</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmaceutical care improved outcomes in epileptic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanjanasilp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peechagoon]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kaewvichit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[RME]]></given-names>
</name>
</person-group>
<source><![CDATA[CMU J Nat Sci]]></source>
<year>2008</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-45</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of quality of life in people with epilepsy and their gender differences]]></article-title>
<collab>Wu X et al</collab>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2011</year>
<volume>22</volume>
<page-range>692-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognosis of chronic and newly diagnosed epilepsy revisiting temporal aspects]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shorvon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Luciano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Neurol]]></source>
<year>2007</year>
<volume>20</volume>
<page-range>208-12</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Early seizure and frequency aetiology predict long-term medical outcome in childhood-onset epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sillanpäa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Brain]]></source>
<year>2009</year>
<volume>132</volume>
<page-range>989-98</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerts]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arts]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Stroink]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Peeters]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Course and outcome of chilhood epilepsy a 15-year follow-up of the Dutch Study of Epilepsy in Chilhood]]></article-title>
<collab>Peters B et al</collab>
<source><![CDATA[Epilepsia]]></source>
<year>2010</year>
<volume>51</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1189-97</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[When to start antiepileptic drug treatment and with what evidence]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2008</year>
<volume>48</volume>
<page-range>140-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
